Intracranial ependymomas: treatment results and prognostic factors.
Forty-nine intracranial ependymoma patients were postoperatively irradiated with craniospinal, cranial, or wide local fields. Thirty-two patients received an adjuvant chemotherapy regimen of vincristine and CCNU with or without procarbazine. The 10-year actuarial overall and progression-free survival rates were 57% and 57%, respectively. Age was the only significant prognostic factor in favor of adults (p = 0.01).
Zorlu
A F
AF
Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Atahan
I L
IL
Akyol
F H
FH
Gürkaynak
M
M
Ozyar
E
E
D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004806:Ependymoma / Q000532:radiotherapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D011867:Radioisotope Teletherapy; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D003037:Cobalt Radioisotopes; D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine